Literature DB >> 2011422

Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial.

P H Kaleida1, M L Casselbrant, H E Rockette, J L Paradise, C D Bluestone, M M Blatter, K S Reisinger, E R Wald, J S Supance.   

Abstract

A total of 536 infants and children with acute otitis media were randomly assigned to one of six consistent year-long regimens involving the treatment of nonsevere episodes with either amoxicillin or placebo, and severe episodes with either amoxicillin, amoxicillin and myringotomy, or, in children aged 2 years or older, placebo and myringotomy. Nonsevere episodes had more favorable outcomes in subjects assigned to treatment with amoxicillin than with placebo, as measured by the proportions that resulted in initial treatment failure (3.9% vs 7.7%, P = .009) and the proportions in which middle-ear effusion was present at 2 and 6 weeks after onset (46.9% vs 62.5%, P less than .001; and 45.9% vs 51.5%, P = .09, respectively). In subjects whose entry episode was non-severe, those assigned to amoxicillin treatment had less average time with effusion during the succeeding year than those assigned to placebo treatment (36.0% vs 44.4%, P = .004), but recurrence rates of acute otitis media in the two groups were similar. In the 2-year-and-older age group, severe episodes resulted in more initial treatment failures in subjects assigned to receive myringotomy alone than in subjects assigned to receive amoxicillin with, or without, myringotomy (23.5% vs 3.1% vs 4.1%, P = .006). In the study population as a whole, severe episodes in subjects assigned to receive amoxicillin alone, and amoxicillin with myringotomy, had comparable outcomes. It is concluded that children with acute otitis media should routinely be treated with amoxicillin (or an equivalent antimicrobial drug). The data provide no support for the routine use of myringotomy either alone or adjunctively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011422

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  32 in total

1.  Is antimicrobial therapy of value for all children with acute otitis media?

Authors:  J O Klein
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Current Concepts of Therapy for Otitis Media.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 3.  Acute otitis media.

Authors:  S Pirozzo; C Del Mar
Journal:  West J Med       Date:  2001-12

4.  Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years.

Authors:  R A Damoiseaux; F A van Balen; A W Hoes; T J Verheij; R A de Melker
Journal:  BMJ       Date:  2000-02-05

5.  Epidemiology and pharmacoeconomic issues relating to acute respiratory tract infections and acute uncomplicated infections of the urinary tract.

Authors:  N M Graham
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 6.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

7.  Management of acute otitis media.

Authors:  S Forgie; G Zhanel; J Robinson
Journal:  Paediatr Child Health       Date:  2009-09       Impact factor: 2.253

8.  Treatment of acute otitis media in children under 2 years of age.

Authors:  Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Nader Shaikh; Ellen R Wald; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Sonika Bhatnagar; Mary Ann Haralam; Lisa M Zoffel; Carly Jenkins; Marcia A Pope; Tracy L Balentine; Karen A Barbadora
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 9.  The role of antibacterial therapy of acute otitis media in promoting drug resistance.

Authors:  C E Johnson; S Belman
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 10.  Acute otitis media in children: association with day care centers--antibacterial resistance, treatment, and prevention.

Authors:  David Greenberg; Sigalit Hoffman; Eugene Leibovitz; Ron Dagan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.